$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000162828017011106 Filed on November 08, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$18.00K	$18.00K	$18.00K
YoY Change	0.0%	-91.18%	-99.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.260M	$2.740M	$4.780M
YoY Change	-31.8%	-43.39%	-11.97%
% of Gross Profit
Research & Development	$10.47M	$12.70M	$14.98M
YoY Change	-30.11%	-12.76%	17.12%
% of Gross Profit
Depreciation & Amortization	$580.0K	$580.0K	$690.0K
YoY Change	-15.94%	-12.12%	68.29%
% of Gross Profit
Operating Expenses	$13.72M	$15.43M	$19.76M
YoY Change	-30.55%	-20.43%	8.46%
Operating Profit		-$15.42M
YoY Change		-19.68%
Interest Expense	-$800.0K	$580.0K	-$270.0K
YoY Change	196.3%	3.57%	-292.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.51M	-$15.84M	-$20.02M
YoY Change	-27.52%	-18.86%	177.29%
Income Tax	-$36.31M	-$7.000K	$10.00K
% Of Pretax Income
Net Earnings	-$14.45M	-$15.83M	-$20.02M
YoY Change	-27.83%	-18.91%	177.06%
Net Earnings / Revenue	-80266.67%	-87933.33%	-111222.22%
Basic Earnings Per Share			-$0.38
Diluted Earnings Per Share	-$1.663M	-$2.108M	-$4.540M
COMMON SHARES
Basic Shares Outstanding	104.0M shares	103.8M shares	52.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.10M	$71.40M	$76.10M
YoY Change	-21.02%	-22.05%	-33.3%
Cash & Equivalents	$13.52M	$20.22M	$14.94M
Short-Term Investments	$46.60M	$51.10M	$61.20M
Other Short-Term Assets	$1.506M	$1.752M	$4.154M
YoY Change	-63.75%	556.18%	447.3%
Inventory
Prepaid Expenses	$4.783M	$5.912M	$5.600M
Receivables	$400.0K	$500.0K	$1.700M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$66.74M	$79.57M	$87.47M
YoY Change	-23.71%	-22.62%	-34.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.708M	$10.17M	$11.83M
YoY Change	-17.94%	-15.53%	119.07%
Goodwill
YoY Change
Intangibles	$775.0K	$802.0K	$1.015M
YoY Change	-23.65%	-23.69%	-6.11%
Long-Term Investments
YoY Change
Other Assets	$590.0K	$307.0K	$342.0K
YoY Change	72.51%	-10.5%	-0.58%
Total Long-Term Assets	$11.07M	$11.28M	$13.19M
YoY Change	-16.03%	-16.04%	93.22%
TOTAL ASSETS
Total Short-Term Assets	$66.74M	$79.57M	$87.47M
Total Long-Term Assets	$11.07M	$11.28M	$13.19M
Total Assets	$77.81M	$90.85M	$100.7M
YoY Change	-22.7%	-21.86%	-28.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.743M	$5.229M	$5.840M
YoY Change	-1.66%	-8.65%	114.94%
Accrued Expenses	$4.941M	$4.770M	$5.577M
YoY Change	-11.4%	-5.84%	-11.88%
Deferred Revenue	$72.00K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.90M
YoY Change
Total Short-Term Liabilities	$32.60M	$11.76M	$13.81M
YoY Change	136.11%	-10.6%	9.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$19.80M	$19.80M
YoY Change	-100.0%	0.0%
Other Long-Term Liabilities	$0.00	$351.0K	$144.0K
YoY Change	-100.0%	-95.93%
Total Long-Term Liabilities	$0.00	$351.0K	$144.0K
YoY Change	-100.0%	-95.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.60M	$11.76M	$13.81M
Total Long-Term Liabilities	$0.00	$351.0K	$144.0K
Total Liabilities	$42.59M	$42.27M	$44.59M
YoY Change	-4.47%	-3.02%	162.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$345.9M	-$331.4M	-$273.4M
YoY Change	26.53%	30.82%	42.73%
Common Stock	$381.2M	$380.1M	$329.5M
YoY Change	15.68%	16.55%	4.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.22M	$48.58M	$56.08M
YoY Change
Total Liabilities & Shareholders Equity	$77.81M	$90.85M	$100.7M
YoY Change	-22.7%	-21.86%	-28.65%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$14.45M	-$15.83M	-$20.02M
YoY Change	-27.83%	-18.91%	177.06%
Depreciation, Depletion And Amortization	$580.0K	$580.0K	$690.0K
YoY Change	-15.94%	-12.12%	68.29%
Cash From Operating Activities	-$11.10M	-$11.66M	-$15.10M
YoY Change	-26.49%	-24.77%	-11.38%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$100.0K	-$160.0K
YoY Change	-50.0%	-79.17%	-67.35%
Acquisitions
YoY Change
Other Investing Activities	$4.480M	-$23.70M	$15.55M
YoY Change	-71.19%	-795.01%	14.93%
Cash From Investing Activities	$4.400M	-$23.80M	$15.38M
YoY Change	-71.39%	-909.52%	17.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	43.15M	-40.00K
YoY Change	-100.0%	18660.87%	-102.44%
NET CHANGE
Cash From Operating Activities	-11.10M	-11.66M	-15.10M
Cash From Investing Activities	4.400M	-23.80M	15.38M
Cash From Financing Activities	0.000	43.15M	-40.00K
Net Change In Cash	-6.700M	7.690M	240.0K
YoY Change	-2891.67%	-162.37%	-110.21%
FREE CASH FLOW
Cash From Operating Activities	-$11.10M	-$11.66M	-$15.10M
Capital Expenditures	-$80.00K	-$100.0K	-$160.0K
Free Cash Flow	-$11.02M	-$11.56M	-$14.94M
YoY Change	-26.24%	-23.04%	-9.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-271000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5577000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103955147	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Number Of Employees EntityNumberOfEmployees	65	employee
	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
	dei	Trading Symbol TradingSymbol	RGLS
CY2017Q3	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	71400000	USD
CY2017Q1	rgls	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	7400000	USD
	rgls	Noncashor Part Noncash Intangible Assets Accrued Cost Not Yet Paid NoncashorPartNoncashIntangibleAssetsAccruedCostNotYetPaid	5000	USD
	rgls	Noncashor Part Noncash Intangible Assets Accrued Cost Not Yet Paid NoncashorPartNoncashIntangibleAssetsAccruedCostNotYetPaid	0	USD
	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	-1176000	USD
	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	0	USD
	rgls	Short Term Investment Maturity Weighted Average ShortTermInvestmentMaturityWeightedAverage	P2Y
CY2017Q2	rgls	Workforce Reduction Commitment Rate WorkforceReductionCommitmentRate	0.30
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1657000	USD
CY2017Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	532000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5840000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5229000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-525000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4770000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-123000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-104000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	329496000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	379992000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3467000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9453000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1284000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6531000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3131911	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3762952	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1281022	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2531362	shares
CY2016Q4	us-gaap	Assets Assets	100661000	USD
CY2017Q3	us-gaap	Assets Assets	90847000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	87474000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	79566000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	61170000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	51148000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9538000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-102000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	38000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	61236000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	51185000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15960000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14706000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14941000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20222000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1254000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5281000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13440899	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52924805	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	103955147	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52924805	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	103955147	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19549000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61796000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15844000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57438000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8840000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8372000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1993000	USD
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1939000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1589000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1942000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2017Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1300000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2318000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1687000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4842000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13609000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-631000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	634000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2736000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13752000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61825000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19515000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15835000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57596000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-9735000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1124000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3007000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-579000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1187000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-652000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-178000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-418000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1176000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-54000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2405000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1329000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	360000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1015000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	802000	USD
CY2016Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	237000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	608000	USD
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	160000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	559000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	560000	USD
	us-gaap	Interest Expense InterestExpense	674000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	580000	USD
	us-gaap	Interest Expense InterestExpense	1730000	USD
	us-gaap	Interest Paid InterestPaid	518000	USD
	us-gaap	Interest Paid InterestPaid	1444000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	44586000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	42265000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100661000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90847000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13807000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11758000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	19802000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	19845000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20594000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43415000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19927000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	307000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-30000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41775000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47672000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-19519000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-61816000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15828000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-57457000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	19396000	USD
	us-gaap	Operating Expenses OperatingExpenses	62935000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	15433000	USD
	us-gaap	Operating Expenses OperatingExpenses	56479000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19192000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61759000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15415000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56425000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4154000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1752000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	342000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	144000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	351000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	338000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	206000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	6653000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	48000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	746000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	217000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60716000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48539000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5552000	USD
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5912000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	641000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43411000	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	19768000	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	81437000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	58310000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	309000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11830000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10172000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14554000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	124000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2960000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4523000	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49326000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12697000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42727000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1300000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273351000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-331410000	USD
CY2016Q3	us-gaap	Revenues Revenues	204000	USD
	us-gaap	Revenues Revenues	1176000	USD
CY2017Q3	us-gaap	Revenues Revenues	18000	USD
	us-gaap	Revenues Revenues	54000	USD
CY2017Q2	us-gaap	Severance Costs1 SeveranceCosts1	3200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9453000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6531000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8931000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10483174	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10483000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.70
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.62
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.41
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	61170000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	51148000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	56075000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	48582000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52835414	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52776459	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90072045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65550749	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-011106-index-headers.html	Edgar Link	pending
0001628280-17-011106-index.html	Edgar Link	pending
0001628280-17-011106.txt	Edgar Link	pending
0001628280-17-011106-xbrl.zip	Edgar Link	pending
ex-311x20170930.htm	Edgar Link	pending
ex-312x20170930.htm	Edgar Link	pending
ex-321x20170930.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20170930.xml	Edgar Link	completed
rgls-20170930.xsd	Edgar Link	pending
rgls-20170930_cal.xml	Edgar Link	unprocessable
rgls-20170930_def.xml	Edgar Link	unprocessable
rgls-20170930_lab.xml	Edgar Link	unprocessable
rgls-20170930_pre.xml	Edgar Link	unprocessable
rgls20170930-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2017 Q4 Form 10-Q Financial Statement

#000162828017011106 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2017 Q4 Form 10-Q Financial Statement

#000162828017011106 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls